Inhibitors against DNA Polymerase I Family of Enzymes: Novel Targets and Opportunities

Saathvik Kannan,Samuel W. Gillespie,Wendy L. Picking,William D. Picking,Christian L. Lorson,Kamal Singh

DOI: https://doi.org/10.3390/biology13040204

2024-03-22

Biology

Abstract:DNA polymerases replicate cellular genomes and/or participate in the maintenance of genome integrity. DNA polymerases sharing high sequence homology with E. coli DNA polymerase I (pol I) have been grouped in Family A. Pol I participates in Okazaki fragment maturation and in bacterial genome repair. Since its discovery in 1956, pol I has been extensively studied, primarily to gain deeper insights into the mechanism of DNA replication. As research on DNA polymerases advances, many novel functions of this group of polymerases are being uncovered. For example, human DNA polymerase θ (a Family A DNA pol) has been shown to synthesize DNA using RNA as a template, a function typically attributed to retroviral reverse transcriptase. Increased interest in drug discovery against pol θ has emerged due to its roles in cancer. Likewise, Pol I family enzymes also appear attractive as drug-development targets against microbial infections. Development of antimalarial compounds targeting apicoplast apPOL, an ortholog of Pol I, further extends the targeting of this family of enzymes. Here, we summarize reported drug-development efforts against Family A polymerases and future perspective regarding these enzymes as antibiotic targets. Recently developed techniques, such as artificial intelligence, can be used to facilitate the development of new drugs.

biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop new inhibitors for enzymes in the DNA polymerase I family (Family A) to deal with diseases such as cancer, bacterial infections and malaria. Specifically:

1. **Cancer treatment**: Human DNA polymerase θ (Pol θ) plays a crucial role in homologous recombination repair (HR) - deficient cancers. These cancer cells rely on Pol θ for micro - homology - mediated end - joining (MMEJ), so Pol θ has become an important therapeutic target for drug - resistant cancers. By developing inhibitors of Pol θ, the effectiveness of cancer treatment can be improved and the dependence on traditional chemotherapy and radiotherapy can be reduced.

2. **Antibacterial drug development**: Enzymes in the DNA polymerase I family also play important roles in bacteria, such as DNA polymerase I in Escherichia coli. These enzymes are involved in the replication and repair of the bacterial genome, so they have also become important targets for the development of new antibiotics. Using modern technologies such as artificial intelligence and large - scale drug screening can accelerate the discovery of effective inhibitors for these enzymes.

3. **Antimalarial drug development**: The apicoplast DNA polymerase (apPOL) in Plasmodium is essential for the survival of malaria parasites. Since apPOL has low sequence homology but similar structure to human Pol θ, it has become a potential antimalarial drug target. Developing inhibitors against apPOL can provide new treatment methods for malaria.

In summary, this paper aims to explore enzymes in the DNA polymerase I family as new targets for drug development, and summarizes the current research progress of inhibitors for these enzymes, especially Pol θ and apPOL, and proposes future research directions and technical means.